You are here

Opioid-Dependence Drug Bunavail (Buprenorphine/Naloxone Buccal Film) Submitted for FDA Review

Combo product absorbed through cheek or under tongue (August 1)

A New Drug Application (NDA) has been submitted to the FDA for Bunavail (buprenorphine/naloxone buccal film, BioDelivery Sciences International) for the maintenance treatment of opioid dependence. The product will be subject to a 10-month review.

Bunavail delivers buprenorphine across the buccal mucosa. It is formulated with the abuse-deterrent agent naloxone.

Buprenorphine is poorly absorbed from the gastrointestinal tract when administered orally; however, it is absorbed within the oral cavity transmucosally (across the cheek or under the tongue). The drug reduces the craving and withdrawal effects induced by the dependency-causing opioid.

According to the 2010 National Survey on Drug Use and Health, nearly 2 million Americans are dependent on prescription opioids.

Source: BioDelivery Sciences International; August 1, 2013.

Recent Headlines

Citrus, Berries, Broccoli Reduce Risk of Cancer and CVD
Changes in Antibiotic Recommendations for Children
Influences Gene Involved in Circadian Rhythms
‘The Perfect Drug for Trauma-Focused Psychotherapy’
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients